Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Huons Co., Ltd. (243070.KQ)
Seongnam-si, KR
Huons Co., Ltd. operates as a global healthcare company, providing a broad spectrum of medical solutions designed to enhance human health in South Korea and worldwide. Its extensive product line includes a variety of oral solid medications targeting numerous conditions, such as those affecting the circulatory and metabolic systems, pain and inflammation (antipyretic, analgesic, anti-inflammatory), musculoskeletal and digestive health, allergies (antihistamines), respiratory ailments, infections (antibiotics), and products for general well-being, urogenital issues, and various chemotherapeutic applications. The company also manufactures a comprehensive range of injectable pharmaceuticals. These span categories like anesthetics, pain and fever reducers, anti-inflammatory agents, muscle relaxants, antispasmodics, antihistamines, and treatments for circulatory and respiratory system disorders. Further offerings in this format include adrenocortical hormones, enzymes, minerals, solvents, calcium supplements, hemostatics, antidotes, antibiotics, metabolic aids, hyaluronic acid, wellness formulations, anticoagulants, and specialized products for tissue and cell systems. In addition to its pharmaceutical offerings, Huons provides ophthalmic solutions (eye drops), various biological products, and medical devices. Established in 1965 and headquartered in Seongnam, South Korea, the company was initially known as Kwang Myung Pharm before officially changing its name to Huons Co., Ltd. in June 2003.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.82% | -16.00% | +11.36% | +2.80% | +2.98% | +7.50% | +2.44% | -9.54% | -48.83% | -42.19% | -42.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.2% Q1'26: -2.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+51.6% ★ Q1'26: -97.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.6% Q1'26: +9.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.4% Q1'26: -0.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+7.5% ★ Q1'26: -0.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.9% ★ Q1'26: -43.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.46× Q1'26: 5.45× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
284.84B
est: 284.90B (0.0%)
|
328.60B
est: 325.70B (+0.9%)
|
365.02B
est: 363.20B (+0.5%)
|
406.68B
est: 416.67B (-2.4%)
|
436.91B
est: 451.00B (-3.1%)
|
492.39B
est: 492.10B (+0.1%)
|
552.01B
est: 550.23B (+0.3%)
|
590.23B
est: 625.00B (-5.6%)
|
620.77B
est: 614.20B (+1.1%)
|
651.60B
651.60B – 651.60B
+6.1% YoY
|
695.60B
695.60B – 695.60B
+6.8% YoY
|
| EBITDA |
41.47B
est: 41.08B (+1.0%)
|
51.71B
est: 46.96B (+10.1%)
|
60.81B
est: 52.37B (+16.1%)
|
84.32B
est: 60.07B (+40.4%)
|
59.23B
est: 65.02B (-8.9%)
|
60.15B
est: 70.95B (-15.2%)
|
83.84B
est: 79.33B (+5.7%)
|
61.36B
est: 78.82B (-22.2%)
|
72.62B
est: 77.45B (-6.2%)
|
82.17B
82.17B – 82.17B
+6.1% YoY
|
87.72B
87.72B – 87.72B
+6.8% YoY
|
| EBIT |
45.89B
est: 31.91B (+43.8%)
|
56.92B
est: 36.47B (+56.1%)
|
50.95B
est: 40.67B (+25.3%)
|
72.50B
est: 46.66B (+55.4%)
|
46.38B
est: 50.51B (-8.2%)
|
43.41B
est: 55.11B (-21.2%)
|
65.61B
est: 61.62B (+6.5%)
|
40.43B
est: 56.89B (-28.9%)
|
45.62B
est: 55.91B (-18.4%)
|
59.31B
59.31B – 59.31B
+6.1% YoY
|
63.32B
63.32B – 63.32B
+6.8% YoY
|
| Net Income |
35.07B
est: 35.82B (-2.1%)
|
45.23B
est: 43.48B (+4.0%)
|
38.21B
est: 37.15B (+2.8%)
|
55.58B
est: 43.06B (+29.1%)
|
30.75B
est: 45.48B (-32.4%)
|
22.44B
est: 35.01B (-35.9%)
|
50.47B
est: 53.94B (-6.4%)
|
29.45B
est: 53.11B (-44.5%)
|
42.66B
est: 42.54B (+0.3%)
|
40.65B
40.65B – 40.65B
-4.4% YoY
|
45.86B
45.86B – 45.86B
+12.8% YoY
|
| SGA |
76.07B
est: 98.68B (-22.9%)
|
88.08B
est: 112.81B (-21.9%)
|
94.93B
est: 125.80B (-24.5%)
|
135.93B
est: 144.32B (-5.8%)
|
168.79B
est: 156.21B (+8.1%)
|
186.42B
est: 170.45B (+9.4%)
|
193.26B
est: 190.58B (+1.4%)
|
166.78B
est: 205.43B (-18.8%)
|
152.58B
est: 201.88B (-24.4%)
|
214.17B
214.17B – 214.17B
+6.1% YoY
|
228.63B
228.63B – 228.63B
+6.8% YoY
|
| EPS |
2,223.46
est: 2,963.03 (-25.0%)
|
3,786.93
est: 3,596.75 (+5.3%)
|
3,199.95
est: 3,073.10 (+4.1%)
|
4,664.55
est: 3,561.85 (+31.0%)
|
2,596.00
est: 3,761.82 (-31.0%)
|
1,897.05
est: 2,896.00 (-34.5%)
|
4,261.00
est: 4,461.67 (-4.5%)
|
2,489.97
est: 4,433.00 (-43.8%)
|
3,651.41
est: 3,551.00 (+2.8%)
|
3,393.00
3,393.00 – 3,393.00
-4.4% YoY
|
3,828.00
3,828.00 – 3,828.00
+12.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 2/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 2/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 2/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 27.0K | 0.56% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 560.4K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 191.7K | 0.39% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 12.3K | 0.44% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 38.4K | 0.46% |
| 6 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 4.4K | 0.22% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 10.6K | 0.22% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 122.2K | 0.23% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 115.8K | 0.29% |
| 10 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 11.3K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jung-hun Kim | Chief Disclosure Officer | — | — |
| ShinWon Kang | Chief Financial Officer | — | male |
| SooYoung Song | CEO & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 243070.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
